Federated Hermes’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.76K | Buy |
+2,318
| New | +$2.76K | ﹤0.01% | 1936 |
|
|
2024
Q1 | – | Sell |
-226,375
| Closed | -$1.11M | – | 2024 |
|
|
2023
Q4 | $1.11M | Hold |
226,375
| – | – | ﹤0.01% | 1098 |
|
|
2023
Q3 | $2.16M | Sell |
226,375
-78,036
| -26% | -$746K | 0.01% | 892 |
|
|
2023
Q2 | $3.95M | Sell |
304,411
-309,214
| -50% | -$4.01M | 0.01% | 758 |
|
|
2023
Q1 | $7.79M | Sell |
613,625
-209,675
| -25% | -$2.66M | 0.02% | 603 |
|
|
2022
Q4 | $9.48M | Buy |
+823,300
| New | +$9.48M | 0.03% | 547 |
|